Immatics N.V. (IMTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.83
- As of
Kresmion compiles this page from IMTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Immatics N.V. (IMTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-08-26.
See the full IMTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IMTX on one page. Preview it with sample data, then open it live with a free account.
Preview the IMTX dossierActive signals for IMTX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 5.7%, EPS $-0.46 vs $-0.4352 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +15959% to IMTX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 81% of IMTX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 51% of IMTX (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in IMTX
FREE, NO ACCOUNT
Every signal on IMTX, as it fires
You are seeing 5 of 8 signals recorded on IMTX since 2026-05-27.
The five above landed across 2 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IMTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP N44445109 · 2026Q2 | $18.4M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP N44445109 · 2026Q2 | $14.7M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP N44445109 · 2026Q2 | $1.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP N44445109 · 2026Q2 | $599K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IMTX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
IMTX against its peers
IMTX's return on equity of -40.6% ranks in the 53rd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | IMTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Operating margin | n/a | -87.0% | n/a | 8 |
| Net margin | n/a | -106.9% | n/a | 8 |
| Return on equity | -40.6% | -53.8% | 53 | 15 |
| 1 year | n/a | 13.0% | n/a | 16 |
Peers (19): JANX, MNKD, BCAX, MGTX, REPL, VOR, LBRX, SVRA, NBTX, ORIC, CGEM, KURA, DMRA, MLTX, DRTS, RIGL, GLUE, INBX, JBIO. Left out: AVLN (no annual filing), LTGO (no annual filing), AKTS (no annual filing), TRAX (no annual filing), SPTX (no annual filing), ANL (period gap). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (IMTX: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IMTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IMTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.